The following cell populations were identified based on cell marker expression: neutrophils (CD45+CD11b+Ly6C−Ly6G+), monocytes (CD45+ CD11b+Ly-6G−Ly-6Chigh), CD11b+ macrophage (CD45+CD11b+Ly6G−Ly6C−F4/80+), T cells (CD45+CD3+CD4+ or CD8+), B cells (CD45+B220+CD19+), NK cells (CD45+CD3−NK1.1+), DC1 (CD45+CD3−CD19−NK1.1−, MHCII+CD11c+ CD64−CD11b−CD103+ (tumour) XCR1+ (lymphoid tissue)), DC2 (CD45+ CD3−CD19−NK1.1−MHCII+CD11c+CD64−CD11b+CD103/XCR1−), migDC DC1 (CD45+CD3−CD19−NK1.1−MHCII+CD11c+CD64−CD11b+CD103+).
The following antibodies (Biolegend and BD) were used: CD45 (30-F11), CD4 (RM4-5), CD8a (53-6.7), B220 (RA3-6B2), NK1.1 (PK136), CD11b (M1/70), CD11c (N418), CD103 (P84), XCR1 (ZET), CD64 (X54-5/7.1), CD86 (GL-1), PDL1 (10F.9G2), CD27 (LG.3A10), IL-7Ra (A7R34), CXCR5 (L138D7), CX3CR1 (SA011F11), CD5 (53-7.3), CD24 (M1/69), PDL2 (122), Lag3 (C9B7W), TIGIT (GIGD7), TIM-3 (5D12), Ly6C (HK1.4), Ly6G (1A8), TCRb (H57-597), F4/80 (BM8), Ki67 (16A8), T-bet (4B10) and TCF1 (C63D9).